Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting

CONCLUSIONS: The development of a program aimed at optimizing the prescription of Trastuzumab holds the potential to deliver significant cost-savings to hospitals while enhancing the quality of service provided to the patients. This optimization involves using H SC in monotherapy and BS IV in combination therapy administration.PMID:37857129 | DOI:10.1016/j.breast.2023.103588

Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Eric C Barat Marianne L E Arrii Annaelle Soubieux-Bourbon Mika ël Daouphars R émi Varin Patrick R Tilleul Source Type: research